Gilead Sciences Adopts Veeva Vault CRM

Veeva’s Next-Gen CRM Taps Agentic AI, Lands Gilead as Key Client

PLEASANTON, Calif., Sept. 10, 2025 — Veeva Systems (VEEV), a prominent player in cloud solutions for the life sciences industry, announced today that Gilead Sciences, a leading biopharmaceutical company, has adopted Veeva Vault CRM. This move signifies a deepening of the existing partnership between the two firms and a validation of Veeva’s strategic focus on integrating Artificial Intelligence (AI) into its CRM offerings.

“Gilead has consistently been at the forefront of medical innovation, and we are excited to expand our support by extending our partnership to Vault CRM,” said Peter Gassner, CEO of Veeva. This sentiment underscores Veeva’s ambition to become a central technology partner for major pharmaceutical companies, facilitating commercial execution and streamlining operations through its cloud-based platform.

“The adoption of Veeva Vault CRM is an example of our continued commitment to advancing medicine,” stated Anna Åsberg, global CIO at Gilead Sciences. “We see promising potential in Veeva AI to elevate commercial execution.” Gilead expects that the platform’s capabilities, particularly its AI-driven features, will enable them to optimize sales processes, enhance customer engagement, and ultimately accelerate the delivery of life-changing medicines to patients.

Vault CRM represents a core component of the broader Vault CRM Suite, designed to provide a comprehensive foundation for commercial activities within the life sciences sector. Veeva is betting big on AI, with the Veeva AI for Vault CRM package including AI agents focused on pre-call planning, automation for compliant free text communication, and hands-free voice control. This push towards agentic AI aligns with the industry’s broader trend of leveraging machine learning to improve efficiency and unlock new levels of personalized customer service.

Industry analysts believe that Veeva’s focus on AI-powered solutions is a strategic advantage, as pharmaceutical companies increasingly seek ways to leverage data and automation to improve their commercial performance. The implementation of AI in CRM systems offers the potential to streamline workflows, optimize resource allocation, and provide sales teams with valuable insights to make more informed decisions. Veeva’s Vault CRM is designed to specifically address the unique regulatory and compliance challenges within the life sciences industry, providing a competitive edge in a highly regulated market.

About Veeva Systems

Veeva Systems provides cloud-based software, data, and consulting services tailored for the life sciences industry. With a commitment to innovation and customer success, Veeva serves over 1,500 customers, from global pharmaceutical giants to emerging biotechnology companies. Veeva operates as a Public Benefit Corporation, balancing the interests of various stakeholders, including customers, employees, shareholders, and the sector it serves. For more details, please visit veeva.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company dedicated to developing and delivering innovative medicines to prevent and treat life-threatening diseases. With a history of breakthroughs spanning more than three decades, Gilead’s focus areas include HIV, viral hepatitis, COVID-19, cancer, and inflammation. Headquartered in Foster City, California, Gilead operates in more than 35 countries globally.

Veeva Forward-Looking Statements

This announcement contains forward-looking statements regarding Veeva’s products, services, and expected benefits. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could impact Veeva’s results are detailed in the company’s filings with the Securities and Exchange Commission (SEC), including the Form 10-Q for the period ended July 31, 2025, and subsequent SEC filings, available at sec.gov.